PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model

被引：0
|
作者：
Li, Yuan
Du, Yang
Sun, Ting
Xue, Huadan
Tian, Jie
Jin, Zhengyu
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-2660
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2660
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells
    Chang, Chien-Hsing
    Wang, Yang
    Li, Rongxiu
    Rossi, Diane L.
    Liu, Donglin
    Rossi, Edmund A.
    Cardillo, Thomas M.
    Goldenberg, David M.
    CANCER RESEARCH, 2017, 77 (19) : 5384 - 5394
  • [32] TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    LaMontagne, Russell
    Case, Katie
    Tran, Lisa
    Zheng, Hui
    Yang, Michael
    Faustman, Denise
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 124 - 125
  • [33] Paclitaxel affects the efficacy of PD-1 blockade by interfering with lipid metabolism reprogramming in patients with breast cancer
    Mo, Hongnan
    Han, Jiashu
    Zhai, Jingtong
    Sun, Xiaoying
    Guan, Xiuwen
    Qian, Haili
    Ma, Fei
    CANCER RESEARCH, 2024, 84 (09)
  • [34] Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer
    Noguchi, Emi
    Shien, Tadahiko
    Iwata, Hiroji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 321 - 332
  • [35] PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
    Hartkopf, Andreas D.
    Taran, Florin-Andrei
    Wallwiener, Markus
    Walter, Christina B.
    Kraemer, Bernhard
    Grischke, Eva-Maria
    Brucker, Sara Y.
    BREAST CARE, 2016, 11 (06) : 385 - 390
  • [36] Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
    David B. Page
    Harry Bear
    Sangeetha Prabhakaran
    Margaret E. Gatti-Mays
    Alexandra Thomas
    Erin Cobain
    Heather McArthur
    Justin M. Balko
    Sofia R. Gameiro
    Rita Nanda
    James L. Gulley
    Kevin Kalinsky
    Julia White
    Jennifer Litton
    Steven J. Chmura
    Mei-Yin Polley
    Benjamin Vincent
    David W. Cescon
    Mary L. Disis
    Joseph A. Sparano
    Elizabeth A. Mittendorf
    Sylvia Adams
    npj Breast Cancer, 5
  • [37] Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
    Page, David B.
    Bear, Harry
    Prabhakaran, Sangeetha
    Gatti-Mays, Margaret E.
    Thomas, Alexandra
    Cobain, Erin
    McArthur, Heather
    Balko, Justin M.
    Gameiro, Sofia R.
    Nanda, Rita
    Gulley, James L.
    Kalinsky, Kevin
    White, Julia
    Litton, Jennifer
    Chmura, Steven J.
    Polley, Mei-Yin
    Vincent, Benjamin
    Cescon, David W.
    Disis, Mary L.
    Sparano, Joseph A.
    Mittendorf, Elizabeth A.
    Adams, Sylvia
    NPJ BREAST CANCER, 2019, 5 (1)
  • [38] Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy
    Terabe, Masaki
    Robertson, Faith C.
    Clark, Katharine
    De Ravin, Emma
    Bloom, Anja
    Venzon, David J.
    Kato, Shingo
    Mirza, Amer
    Berzofsky, Jay A.
    ONCOIMMUNOLOGY, 2017, 6 (05):
  • [39] Loss of Tumor Intrinsic RIPK1, Antitumor Immune Responses, and the Efficacy of PD-1 Blockade
    Teng, F.
    Wang, P.
    Li, Y.
    Yuan, J.
    Yin, T.
    Shi, X.
    Xu, J.
    Liu, C.
    Yu, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E403 - E403
  • [40] Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment
    Rahimi Kalateh Shah Mohammad, Ghasem
    Ghahremanloo, Atefeh
    Soltani, Arash
    Fathi, Esmat
    Hashemy, Seyed Isaac
    JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (7-8) : 5449 - 5460
12345